Lynda Vrooman
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lynda Vrooman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:41 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02355340 · Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone FractureDana-Farber Cancer Institute · completed · Bone Mineral Density, Childhood Cancer Survivors · principal investigator
- Ph2NCT01643408 · A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyJazz Pharmaceuticals · completed · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma · principal investigator
- Ph3NCT00400946 · 05-001: Treatment of Acute Lymphoblastic Leukemia in ChildrenDana-Farber Cancer Institute · completed · Drug/Agent Toxicity by Tissue/Organ, Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- P01CA068484RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00400946
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00400946
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 12:41 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 268 citationsRCR 8.2
- 209 citationsRCR 6.6
- Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.Pediatr Blood Cancer · 2010127 citationsRCR 3.4
- Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.J Clin Oncol · 200886 citationsRCR 2.2
- Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.J Clin Oncol · 202184 citationsRCR 5.2
- 81 citationsRCR 2.1
- Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.Cancer · 202247 citationsRCR 3.6
- Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.Pediatr Blood Cancer · 201645 citationsRCR 1.6
- Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.Support Care Cancer · 201724 citationsRCR 1.0
- A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.Pediatr Blood Cancer · 201712 citationsRCR 0.5